Holen Sie sich die Stockscreener-App
19.69
2.55%
0.49
Schlusskurs vom Vortag:
$19.20
Offen:
$19.26
24-Stunden-Volumen:
2.52M
Relative Volume:
0.73
Marktkapitalisierung:
$4.70B
Einnahmen:
$426.45M
Nettoeinkommen (Verlust:
$197.67M
KGV:
24.01
EPS:
0.82
Netto-Cashflow:
$110.10M
1W Leistung:
-1.45%
1M Leistung:
-7.25%
6M Leistung:
+3.41%
1J Leistung:
+117.33%
1-Tages-Spanne:
$19.23
$19.97
1-Wochen-Bereich:
$18.95
$20.82
52-Wochen-Spanne:
$8.91
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Firmenname
Adma Biologics Inc
Sektor
Branche
Telefon
(201) 478-5552
Adresse
C/O ADMA BIOLOGICS, INC., RAMSEY
Vergleichen Sie ADMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
19.69 | 4.77B | 426.45M | 197.67M | 110.10M | 0.82 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-19 | Fortgesetzt | Raymond James | Strong Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2021-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Eingeleitet | Jefferies | Buy |
| 2019-04-15 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-12-11 | Bestätigt | Maxim Group | Buy |
| 2017-11-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2016-08-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-07-25 | Bestätigt | Maxim Group | Buy |
| 2015-05-13 | Bestätigt | Maxim Group | Buy |
| 2014-12-08 | Eingeleitet | Oppenheimer | Outperform |
| 2014-12-01 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
(ADMA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Amid Bumpy Biotech Trade, I'm Eyeing These Two Stocks - TheStreet Pro
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - The Globe and Mail
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - MSN
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - Yahoo Finance
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Adma Biologics price target raised to $32 from $25 at Raymond James - TipRanks
Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Future Outlook - GuruFocus
Adma Biologics: Q1 Earnings Snapshot - New Haven Register
ADMA Biologics Reports Strong Q1 2025 Financial Growth - TipRanks
ADMA Biologics Inc earnings missed by $0.01, revenue topped estimates - Investing.com Nigeria
ADMA Options Activity Suggests Anticipated Post-Earnings Volatil - GuruFocus
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, R - GuruFocus
ADMA Biologics Q1 Earnings, Revenue Rise; Shares Fall After Hours - marketscreener.com
Earnings call transcript: ADMA Biologics Q1 2025 sees revenue beat, mixed stock reaction - Investing.com
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
ADMA Biologics (ADMA) Misses Revenue Estimates Despite Strong Growth - GuruFocus
ADMA Biologics Announces $500M Share Repurchase Program - TipRanks
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, Revenue of $114.8M Misses Expectations - GuruFocus
Earnings Flash (ADMA) Adma Biologics Posts Q1 Diluted EPS $0.11, vs. FactSet Est of $0.15 - marketscreener.com
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adma Biologics options imply 10.9% move in share price post-earnings - TipRanks
ADMA Options Activity Suggests Anticipated Post-Earnings Volatility | ADMA Stock News - GuruFocus
3 Mid-Cap Medical Stocks Outperforming the Market - Investing.com
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - Zacks Investment Research
ADMA Biologics Earnings Preview - Nasdaq
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - Zacks Investment Research
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
(ADMA) Technical Data - news.stocktradersdaily.com
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? - MSN
Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know - MSN
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas - The Globe and Mail
Why ADMA Biologics, Inc. (ADMA) Surged on Monday - MSN
Finanzdaten der Adma Biologics Inc-Aktie (ADMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):